Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Tularik |
---|---|
Information provided by: | Tularik |
ClinicalTrials.gov Identifier: | NCT00043459 |
The purpose of the study is to determine whether T900607-sodium is effective and safe in treating non-Hodgkin's lymphoma.
Condition | Intervention | Phase |
---|---|---|
Non-Hodgkin's Lymphoma |
Drug: intravenous T900607-sodium |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria
Exclusion Criteria
United States, California | |
Scripps Health Center | |
La Jolla, California, United States, 92037 | |
United States, Colorado | |
University of Colorado Health Sciences Center | |
Aurora, Colorado, United States, 80010 | |
United States, Illinois | |
Rush Medical Center | |
Chicago, Illinois, United States, 60612 | |
Northwestern University | |
Chicago, Illinois, United States, 60611 | |
United States, New York | |
Weill Medical College of Cornell University | |
New York, New York, United States, 10021 |
Study Chair: | Kerrie Boyd | Tularik |
Study ID Numbers: | T-607-007 |
Study First Received: | August 8, 2002 |
Last Updated: | June 23, 2005 |
ClinicalTrials.gov Identifier: | NCT00043459 |
Health Authority: | United States: Food and Drug Administration |
NHL |
Lymphatic Diseases Immunoproliferative Disorders Lymphoma, small cleaved-cell, diffuse |
Lymphoproliferative Disorders Lymphoma, Non-Hodgkin Lymphoma |
Neoplasms Neoplasms by Histologic Type Immune System Diseases |